BioSpace News Archive

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a “fireside chat” presentation at the Jefferies Virtual London Healthcare Conference on Thursda

Increasing Placebo Responses in PTSD Drug Trials Raise Questions About Current Methods of Measuring or Analyzing PTSD Symptom Change Over Time The U.S. 21 st Century Cures Act Provides Direction on New Statistical Analyses Using Simulations Tonix Plans to Study TNX-102 SL in a New Phase 3 PTSD Trial in Kenya

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming Canaccord Genuity Virtual MedTech & Diagnostics Forum. Management is scheduled to present Thursday, November 19, 2020 at 2:30pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2bio

Revenue for the quarter ended September 30, 2020 was $15.2 million compared to $11.4 million for the quarter ended September 30, 2019, an increase of $3.8 million or 33.0%.

Five Prime Therapeutics, Inc., announced the pricing of an underwritten public offering of 7,200,000 shares of its common stock at a price to the public of $21.00 per share.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on the health security market, announced that Dr. Dennis Hruby, Chief Scientific Officer, will participate in a panel discussion at the Non-Conventional Threats Asia Virtual Conference.

From the public safety point of view, it is very important to keep drunk drivers off the roads.

Opioid treatment is massively noted in severe pain management and chronic cancer treatment. One of the reasons behind their extensive use is high efficacy.

Sequana Medical NV, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies 2020 Virtual London Healthcare Conference taking place from 17 to 19 November 2020.

Zhaoke Ophthalmology Pharmaceutical Ltd. is pleased to announce that the first patient has completed three year enrollment in the Phase III CHAMP study carried out by its partner, Nevakar Inc.